Business Description
Evotec SE
NAICS : 325412
SIC : 2834
ISIN : US30050E1055
Share Class Description:
FRA:EVTA: ADRCompare
Compare
Traded in other countries / regions
EVT.Germany0IRF.UKEVO.USA1EVT.ItalyEVT.BulgariaEVT.Austria IPO Date
2007-12-28Description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.83 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | -7.03 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.7 | |||||
| 3-Year EBITDA Growth Rate | -38.6 | |||||
| 3-Year FCF Growth Rate | -42.2 | |||||
| 3-Year Book Growth Rate | 12.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 16 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.5 | |||||
| 9-Day RSI | 28.18 | |||||
| 14-Day RSI | 31.61 | |||||
| 6-1 Month Momentum % | -47.78 | |||||
| 12-1 Month Momentum % | -52.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | |||||
| Quick Ratio | 1.79 | |||||
| Cash Ratio | 1.17 | |||||
| Days Inventory | 18.73 | |||||
| Days Sales Outstanding | 64.71 | |||||
| Days Payable | 64.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -7.84 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 20.16 | |||||
| Operating Margin % | -10.09 | |||||
| Net Margin % | -11.68 | |||||
| FCF Margin % | -28.9 | |||||
| ROE % | -7.99 | |||||
| ROA % | -4.02 | |||||
| ROIC % | -4.2 | |||||
| ROC (Joel Greenblatt) % | -11.45 | |||||
| ROCE % | -4.97 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 192.31 | |||||
| Shiller PE Ratio | 59.53 | |||||
| PS Ratio | 1.97 | |||||
| PB Ratio | 1.39 | |||||
| Price-to-Tangible-Book | 1.89 | |||||
| EV-to-EBIT | -18.4 | |||||
| EV-to-Forward-EBIT | 67.01 | |||||
| EV-to-EBITDA | -18.4 | |||||
| EV-to-Forward-EBITDA | 13.94 | |||||
| EV-to-Revenue | 2.11 | |||||
| EV-to-Forward-Revenue | 1.8 | |||||
| EV-to-FCF | -7.32 | |||||
| Price-to-Projected-FCF | 2.65 | |||||
| Price-to-Median-PS-Value | 0.29 | |||||
| Earnings Yield (Greenblatt) % | -5.43 | |||||
| FCF Yield % | -14.63 | |||||
| Forward Rate of Return (Yacktman) % | 23.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evotec SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 776.596 | ||
| EPS (TTM) (€) | -0.255 | ||
| Beta | 1.57 | ||
| Volatility % | 60.3 | ||
| 14-Day RSI | 31.61 | ||
| 14-Day ATR (€) | 0.186367 | ||
| 20-Day SMA (€) | 4.647 | ||
| 12-1 Month Momentum % | -52.53 | ||
| 52-Week Range (€) | 4.08 - 12 | ||
| Shares Outstanding (Mil) | 354.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evotec SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evotec SE Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Evotec SE Frequently Asked Questions
What is Evotec SE(FRA:EVTA)'s stock price today?
The current price of FRA:EVTA is €4.08. The 52 week high of FRA:EVTA is €12.00 and 52 week low is €4.08.
When is next earnings date of Evotec SE(FRA:EVTA)?
The next earnings date of Evotec SE(FRA:EVTA) is 2024-08-29 Est..
Does Evotec SE(FRA:EVTA) pay dividends? If so, how much?
Evotec SE(FRA:EVTA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers